{"id":"aci-7104-056-at-dose-a","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to tau protein aggregates, thereby reducing their formation and promoting their clearance. This mechanism is thought to be beneficial in treating tauopathies such as Alzheimer's disease.","oneSentence":"ACI-7104.056 is a tau aggregation inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:46.593Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT06015841","phase":"PHASE2","title":"A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AC Immune SA","startDate":"2023-07-24","conditions":"Parkinson Disease, Parkinson Disease 6, Early-Onset","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1897,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACI-7104.056 at Dose A","genericName":"ACI-7104.056 at Dose A","companyName":"AC Immune SA","companyId":"ac-immune-sa","modality":"Biologic","firstApprovalDate":"","aiSummary":"ACI-7104.056 is a tau aggregation inhibitor. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}